Holen Sie sich die Stockscreener-App
3.14
53.17%
1.09
Handel nachbörslich:
3.43
0.29
+9.24%
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors - Marketscreener.com
Aclaris Therapeutics (ACRS): Strategic Alliance with Biosion Ignites 53% Stock Surge - BP Journal
Aclaris stock rallies 53% amid licensing deal, Piper upgrade (NASDAQ:ACRS) - Seeking Alpha
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More
Aclaris secures $80 million in private stock sale - Investing.com
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - The Manila Times
Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewswire
Aclaris Therapeutics Announces Exclusive, Global License - GlobeNewswire
Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc - GuruFocus.com
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Position Boosted by BML Capital Management LLC - MarketBeat
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week - Simply Wall St
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts - Yahoo Finance
Aclaris stock touches 52-week high at $2.68 amid market fluctuations By Investing.com - Investing.com South Africa
Aclaris stock touches 52-week high at $2.68 amid market fluctuations - Investing.com
FY2024 EPS Estimates for ACRS Reduced by Leerink Partnrs - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by StockNews.com - Defense World
Aclaris Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Aclaris Therapeutics Reports Positive Q3 2024 Milestones - TipRanks
Aclaris: Q3 Earnings Snapshot - The Washington Post
Aclaris Therapeutics Inc earnings missed by $0.10, revenue topped estimates - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK
Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright - MarketBeat
Meeder Advisory Services Inc. Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Defense World
William Blair Investment Management LLC Sells 17,390 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat
5.04%
3.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):